Repligen (RGEN)

Executive Summary

Repligen has successfully transformed from a drug developer into a leading bioprocessing technology company, providing critical solutions for biologic drug manufacturing. Its product portfolio spans chromatography, tangential flow filtration, fluid management, and process analytics, enabling efficient production of monoclonal antibodies, gene therapies, and vaccines. With a market cap of ~$6.3B, Repligen benefits from secular growth in biopharma outsourcing and increasing demand for single-use technologies and process intensification. The company’s strong intellectual property, deep customer relationships with top 20 pharma firms, and global manufacturing footprint position it well to capture market share. Looking ahead, Repligen’s growth is underpinned by innovation in its core platforms, including the Opus® chromatography skids, XCell™ ATF systems, and NGL Impact™ AAV affinity resins. The company also pursues strategic acquisitions and partnerships to expand its offerings. While near-term headwinds from biotech funding volatility may persist, long-term fundamentals remain robust. Repligen’s ability to consistently deliver high-margin, recurring revenue from consumables and capital equipment supports a strong conviction in its investment thesis.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Opus® Chromatography Column with Enhanced Capacity85% success
• TBDMajor Multi-Year Supply Agreement with a Top 10 Biopharma for Filtration and Chromatography Solutions60% success
• Q1 2026Better-than-Expected Q4 2025 Earnings with Raised FY2026 Revenue Guidance70% success